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summarizing evidence for risk assessment, resuscitation, 
blood transfusion, medical and endoscopic therapy, and 
early post-endoscopic management. We will not review 
interventions for long term secondary prevention of 
bleeding, such as testing for and treating Helicobacter 
pylori infection, use of non-steroidal anti-inflammatory 
drugs (NSAIDs), or maintenance antisecretory therapy.
Upper gastrointestinal bleeding is managed by many cli-
nicians across many specialties, including emergency room 
physicians, hospitalists, internists, gastroenterologists, 
surgeons, interventional radiologists, and hematologists.
A variety of topics—including risk assessment, the 
threshold for blood transfusion, the timing of endoscopy, 
and medical and endoscopic therapies—have continued to 
evolve in recent years. In addition, it has become increas-
ingly important and complex to determine the appropriate 
management of patients who need antithrombotic agents, 
with gastroenterological, cardiovascular, and hematologi-
cal aspects needing to be considered.
This article provides a comprehensive and evidence based 
summary of the assessment and management of patients 
with acute upper gastrointestinal bleeding, which is relevant 
to clinician specialists, academics, and clinical researchers. 
A summary of management is provided in the box.
S TAT E  O F  T H E  A R T  R E V I E W  
Introduction
Upper gastrointestinal bleeding is a common medical 
emergency worldwide and refers to bleeding from the 
esophagus, stomach, or duodenum. Patients present with 
hematemesis (bloody or coffee ground emesis) or melena, 
although hematochezia can occur in the context of a major 
bleed and is typically associated with hemodynamic insta-
bility. Patients with melena present with lower hemo-
globin values than patients with hematemesis, probably 
because presentation is more likely to be delayed.1 There-
fore, patients with melena more often require transfusion, 
although mortality is lower in patients with melena than 
in those with hematemesis in some series.1 Numerous 
improvements in the management of upper gastrointesti-
nal bleeding have been incorporated into clinical practice 
in recent years. However, many patients now have risk 
factors for a poorer outcome, including increasing age and 
major medical comorbidities.2
Although the cause of a bleeding episode is uncertain 
until endoscopy is undertaken, guidelines often separate 
upper gastrointestinal bleeding into variceal and non-
variceal bleeding because management and outcomes 
differ.3-9 This article covers the acute management of 
patients with overt upper gastrointestinal bleeding, 
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Overall quality of evidence
Numerous randomized controlled trials (RCTs) and 
meta-analyses have assessed the use of medical and 
endoscopic therapy, and the optimal blood transfusion 
strategy in patients with acute upper gastrointestinal 
bleeding, thereby providing high quality data to guide 
management. Although the evidence regarding resuscita-
tion, risk assessment, timing of endoscopy, and reintro-
duction of antithrombotic drugs is of lower quality, large 
recent studies in these areas have helped inform patient 
management.
Incidence
The incidence of upper gastrointestinal bleeding in the 
United Kingdom in the 1990s was 103-172/100 000 
adults per year.10 11 Recent reports from the United States 
using nationwide administrative databases indicate that 
the incidence of hospital admission for the condition 
was 61-78 per 100 000 persons in 2009-2012.12-14 Peptic 
ulcers are the most common cause of hospital admission 
for upper gastrointestinal bleeding, accounting for just 
over half of all cases.12 14 The incidence of hospital admis-
sion for the condition has decreased 21-23% during the 
past 10 years.12 14 This decrease is largely accounted 
for by decreases in peptic ulcer bleeding (and bleeding 
ascribed to “gastritis”) probably because of the decreas-
ing prevalence of H pylori and increasing use of antisecre-
tory drugs. Case fatality rates from these database studies 
were low, in the range of 1.9-2.5%.12-14 By contrast, large 
observational cohort studies from Europe suggest higher 
fatality rates of around 10%.15 16 The reason for these 
differences is unknown but might be partly related to 
reliance on coding in database studies and differences 
in practice, such as low risk patients being more often 
managed in outpatient settings in Europe.
Sources and selection criteria
We searched PubMed, Medline, and Cochrane databases 
from 2010 to August 2018 using the search terms gastro-
intestinal hemorrhage, peptic ulcer bleeding, and variceal 
bleeding. References were also identified from the inter-
national, UK, European, American, and Asia-Pacific 
guidelines on upper gastrointestinal bleeding published 
during this period in addition to relevant review articles. 
We selected systematic reviews, meta-analyses, RCTs, and 
observational studies (excluding case reports and small 
(<15 cases) case series). We also excluded articles that 
were not peer reviewed and those not published in Eng-
lish. Studies were prioritized by design, as noted above, 
and by patient numbers, quality, and publication date.
Initial resuscitation
As with any new patient with a medical emergency, the 
initial clinical evaluation of patients presenting with 
upper gastrointestinal bleeding involves assessment of 
the patient’s airway, breathing, and circulation. Many 
patients are hemodynamically stable at presentation, 
but for those with major bleeding, early resuscitation is 
essential. In general, two large bore intravenous cannu-
lae are inserted, although central venous access may be 
preferred in certain cases. Regular monitoring of pulse, 
blood pressure, and oxygen saturations is crucial. Hypo-
tension is associated with increased mortality; a multi-
center observational study of 1882 patients reported an 
odds ratio of 9.8 (95% confidence interval 5.1 to 19) with 
systolic blood pressure <90 mm Hg versus ≥90 mm Hg.11 
Tracheal intubation may be used to protect the airway in 
patients with severe ongoing hematemesis, especially in 
those at increased risk of aspiration (such as those with 
an altered mental status or lack of gag reflex).
No RCTs have assessed fluid resuscitation in upper gas-
trointestinal bleeding. By contrast, a comparative study 
and an RCT in patients with hemorrhagic shock as a result 
of trauma suggest that a more restrictive fluid resuscita-
tion may be better (or not worse) than more intensive fluid 
resuscitation.17 18 The choice of intravenous fluid for ini-
tial resuscitation is unclear, with crystalloids or colloids 
often being used while the need for the transfusion of 
blood products is assessed. A meta-analysis of 70 trials 
with 22 392 patients found no difference in mortality 
between colloid and crystalloid solutions for fluid resus-
citation in critically ill patients: relative risk 1.01 (0.93 to 
1.10) for albumin or plasma proteins versus crystalloid 
solutions, and similar negative results when other col-
loids were compared with crystalloids.19 An RCT of 15 
802 critically ill hospital inpatients found reduced acute 
SUMMARY OF THE MANAGEMENT OF UPPER GASTROINTESTINAL BLEEDING
Pre-endoscopic management
• Hemodynamic assessment and resuscitation as needed
• Blood transfusion at a hemoglobin threshold of 70-80 g/L; higher threshold if severe 
bleeding with hypotension
• Risk assessment:
-If Glasgow-Blatchford score ≤1 consider outpatient endoscopy and management
• Erythromycin (as a prokinetic agent) and proton pump inhibitor may be considered
• Patients with cirrhosis should receive vasoactive drugs and antibiotics
Endoscopic
• Endoscopy is generally recommended within 24 hours in patients admitted to hospital
 – If the patient has severe bleeding with hemodynamic instability, urgent endoscopy 
should be performed after resuscitation
• Ulcers with active bleeding and non-bleeding visible vessels should receive endoscopic 
therapy; endoscopic therapy may also be used for ulcers with adherent clots
• Injection therapy (eg, epinephrine), thermal probes (eg, bipolar electrocoagulation, heater 
probe), or clips should be used
• Epinephrine injection should always be followed by a second modality
• Recurrent bleeding should be treated with repeat endoscopic therapy but subsequent 
bleeding by transarterial embolization or surgery
• Esophageal variceal bleeding should be treated with ligation and gastric varices with the 
injection of tissue adhesive
• Refractory variceal bleeding should be treated with transjugular portosystemic shunt
• For massive refractory esophageal variceal bleeding a removable covered metal stent is 
preferred to balloon tamponade as a temporizing measure
Post-endoscopic management
• Patients who have ulcers with high risk lesions (active bleeding, visible vessel, adherent clot) 
should receive high dose proton pump inhibitors for 72 h
• Patients with cirrhosis should continue antibiotics for up to seven days regardless of the 
bleeding source
• Variceal bleeding should be treated with vasoactive drugs for up to five days
• When used for secondary prevention, aspirin should be continued or reintroduced soon after 
hemostasis is achieved
• Early reintroduction of other antithrombotic drugs is also recommended after hemostasis is 
achieved to reduce thrombotic events and death
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kidney injury (odds ratio 0.91, 0.84 to 0.99) and a trend 
towards reduced mortality in hospital (10.3% v 11.1%; 
P=0.08) with balanced crystalloids versus saline.20 
Whether these data can be fully extrapolated to upper 
gastrointestinal bleeding is uncertain.
Red blood cell transfusion
A meta-analysis of 31 RCTs comprising 12 587 patients 
in a variety of populations found that a more restrictive 
approach to red cell transfusion (variably defined at 
hemoglobin threshold 70-90 g/L) does not adversely affect 
outcomes; hospital mortality was lower with a restrictive 
strategy but 30 day mortality was not significantly differ-
ent (risk ratio 0.97, 0.81 to 1.16).21 This systematic review 
concluded that a restrictive policy seemed to be safe in 
patients with underlying cardiovascular disease but no 
evidence was available for patients presenting with acute 
coronary syndrome. On that basis, current US guidelines 
recommend transfusion at a threshold of hemoglobin of 
70 g/L for hemodynamically stable adult inpatients and 
80 g/L for those undergoing orthopedic or cardiac surgery 
or with pre-existing cardiovascular disease.22 Others have 
suggested a threshold in patients with cardiovascular dis-
ease of ≥80 g/L.23
Importantly, results for the general populations 
described above may not be applicable to those with upper 
gastrointestinal bleeding. In such patients a restrictive 
transfusion approach appears not only to be safe but also 
to provide clinical benefit for rebleeding and mortality. A 
small study in 1986 first showed reduced rebleeding with 
restrictive transfusion.24 A large high quality Spanish RCT 
in 921 patients found significantly lower mortality at six 
weeks (hazard ratio 0.55, 0.33 to 0.92) and rebleeding 
(0.68, 0.47 to 0.98) with a transfusion hemoglobin thresh-
old of 70 g/L versus 90 g/L.25 A subsequent six center 
cluster randomized feasibility trial in the UK reported no 
benefit from a liberal transfusion policy when hemoglobin 
thresholds of 80 g/L versus 100 g/L were compared (mor-
tality difference −1%, −8% to 6% in 640 patients).26 A 
meta-analysis of five RCTs comprising 1965 patients with 
upper gastrointestinal bleeding reported that restrictive 
transfusion was associated with lower mortality (relative 
risk 0.65, 0.44 to 0.97) and reduced rebleeding (0.58, 
0.40 to 0.84) (fig 1).27
Thus, in most patients with upper gastrointestinal 
bleeding, red cell transfusion should be withheld until 
a hemoglobin threshold of 70-80 g/L is reached.5 6 28 
Patients with severe bleeding and hemodynamic com-
promise, who were generally excluded from the trials 
described above, require transfusion at higher thresholds 
because their hemoglobin will equilibrate to much lower 
levels as their intravascular volume is repleted with fluid. 
Transfusion thresholds in patients with cardiovascular 
disease, especially those with acute coronary syndrome, 
are less certain, but thresholds of 80 g/L or higher are vari-
ably recommended.22 23
Risk assessment
Many risk assessment scores have been developed for 
patients with upper gastrointestinal bleeding, includ-
ing those that can be calculated early after presentation 
(pre-endoscopy) and those that include endoscopic find-
ings.29-34 They were designed to predict a variety of end-
points. We believe pre-endoscopy scores are of greater 
practical use because it is probably most important to 
predict risk soon after presentation to help direct man-
agement. The use of risk scores has been recommended to 
stratify patients into those at higher or lower risk of poor 
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Fig 1 |  Blood transfusion meta-analysis: liberal versus restrictive transfusion for (A) mortality and (B) rebleeding.27 Reproduced 
with permission from Elsevier. Abbreviations: CI=confidence interval; RR=relative risk.
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outcome.3 6 This enables patients predicted to be high risk 
to be managed in high dependency or intensive care units 
and receive urgent endoscopy, whereas those at very low 
risk can be managed as outpatients.
The most well established and commonly used pre-
endoscopic scores are the Glasgow Blatchford score 
(GBS), the pre-endoscopic or “admission” Rockall score, 
and the AIMS65score (Albumin <3 mg/dL, International 
normalized ratio >1.5, altered Mental status, Systolic 
blood pressure <90 mm Hg, age >65 years).29 32 34 The 
GBS was developed to predict a composite of clinical 
intervention or death, whereas the other two were 
designed to predict death. Many studies have compared 
these and other scores, and GBS seems to be superior at 
predicting a combined endpoint of intervention or death 
(fig 2).35-37
These risk assessment scores cannot precisely identify 
individual high risk patients who will definitely die if 
they do not receive the intervention. Therefore, they have 
limited clinical utility for predicting which patients are at 
higher risk. However, risk scores do seem to have a clini-
cal role in identifying patients who are at very low risk.38 
When aiming to identify a cohort of patients who are at 
very low risk and could be managed as outpatients, it is 
important to achieve a very high sensitivity so that almost 
no patients who may come to harm are sent home.
A systematic review of 16 studies on the use of pre-
endoscopy scores in emergency departments to predict 
intervention, rebleeding, or death concluded that a GBS 
of zero provided the highest sensitivity (0.99), although 
specificity was very low (0.08).39 In 2012, both US and UK 
guidelines recommended that a GBS of zero could be used 
to identify very low risk patients who could avoid admis-
sion and be offered outpatient endoscopy.4 28
Subsequently two large international comparative 
studies of risk assessment scores, with 3012 and 2305 
patients, were published.35 40 These studies reported that 
GBS ≤1 was the optimum low risk threshold, with a sen-
sitivity of 99% and specificity of 35-40%. The authors 
suggested that this threshold could be used to identify 
patients who could be safely discharged from the emer-
gency department for outpatient management, thereby 
avoiding admission in 19-24% of patients presenting 
with upper gastrointestinal bleeding. This approach has 
been accepted by recent European and Asia-Pacific guide-
lines.5 6 No high quality interventional trial has assessed 
outcomes after the introduction of a risk score, although 
a pre-post design study showed the safety of outpatient 
management in 84 patients with a GBS score of zero.38
Management of patients taking antithrombotic drugs
The increasing use of antiplatelet and anticoagulant 
(antithrombotic) medication in the management of car-
diovascular disease means that many patients now pre-
senting with upper gastrointestinal bleeding are taking 
these drugs. A recent multicenter observational study 
of 619 patients requiring endoscopic therapy for upper 
gastrointestinal bleeding reported that 44% were taking 
an antithrombotic drug at presentation, with 25% taking 
more than one.41 Although these drugs are a recognized 
risk factor for upper gastrointestinal bleeding,42 43 no 
clear evidence indicates that their use worsens outcomes 
after the bleed.41 44
The 2016 US guideline on management of antithrom-
botic agents for patients undergoing endoscopy suggests 
that platelet transfusion is an option for life threaten-
ing or serious bleeding in patients taking antiplatelet 
agents.45 However, observational studies have failed to 
identify clinical benefit, and a cohort study with 408 
patients showed significantly higher mortality with plate-
let transfusion (odds ratio 5.6, 1.5 to 27.1).46 This find-
ing led the recent Asia-Pacific guideline panel to suggest 
that platelet transfusions should not be used in patients 
taking antiplatelet agents who present with upper gas-
trointestinal bleeding.6 Platelet dysfunction may also be 
present in patients on hemodialysis or those who have 
had cardiac bypass surgery.47
Less information is available regarding the manage-
ment of anticoagulants, including warfarin and the newer 
direct oral anticoagulants (DOACs), in patients with upper 
gastrointestinal bleeding. For patients taking warfarin, 
recent guidelines suggested the use of prothrombin com-
plex concentrate (PCC) along with vitamin K to prevent 
rebound coagulopathy in patients with a life threatening 
bleed or hemodynamic instability.5 6 PCC is preferable 
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Fig 2 |  Comparison of five upper gastrointestinal bleeding risk scores in prediction of the need 
for any intervention (transfusion, endoscopic therapy, interventional radiology, or surgery) 
or 30 day mortality (n=1704).35 Abbreviations: AIMS65=see text; ARS=admission Rockall 
score; AUROC=area under the receiver operating characteristic curve; FRS=full Rockall score; 
GBS=Glasgow Blatchford score; PNED=Progetto Nazionale Emorragia digestive score.
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to fresh frozen plasma because of the smaller volume 
needed, its more rapid onset, lack of the need to check 
the patient’s blood group, and the minimal infectious 
risk.5 US guidelines suggest either four factor PCC plus 
vitamin K or fresh frozen plasma.45
Guidelines also suggest that the international normal-
ized ratio (INR) should be corrected to <2.5 if possible 
before undertaking endoscopy, with the potential need 
for endoscopic therapy if the clinical situation allows.5 45 
This suggestion is based on observational studies which 
indicate that the outcome after endoscopic therapy is 
similar in patients with an INR of 1.3-2.7 to that in those 
not taking warfarin.48 49 Other studies report that the INR 
value does not predict rebleeding.50
Data on DOACs are limited, but because of their short 
half lives (5-17 h), anticoagulant activity wanes rapidly 
over one to two days (in the absence of renal disease). 
Thus, European guidelines state that “time is the most 
important antidote against DOACs.”5 Although PCC may 
be of some use in severe bleeding, particularly for Xa 
inhibitors, neither vitamin K nor fresh frozen plasma 
has been shown to be beneficial.5 51 Reversal agents for 
dabigatran (idarucizumab)52 and the factor Xa inhibitors 
(andexanet alfa)53 are now approved in the US. Their role 
in patients with upper gastrointestinal bleeding is unclear 
given the uncertain risk of thrombotic events and the 
short half lives of DOACS. They would mainly be used in 
patients with a severe ongoing bleed, especially if DOAC 
ingestion was recent or if renal disease was present.
Coagulopathy and thrombocytopenia in patients with 
cirrhosis
Interpretation of the complex clotting abnormalities seen 
in cirrhosis can be difficult. Patients with cirrhosis have 
parallel decreases in procoagulant and anticoagulant 
factors.54 The prothrombin time measures procoagulant 
activity only; therefore, prothrombin time or INR is not a 
reliable indicator of coagulation status in patients with 
cirrhosis.54 Fresh frozen plasma is often given to patients 
with upper gastrointestinal bleeding, cirrhosis, and 
raised prothrombin time, but it has not been shown to 
provide benefit and could have adverse effects. For these 
reasons, the most recent US guidelines on portal hyper-
tensive bleeding recommend against correcting INR with 
fresh frozen plasma or recombinant factor VIIa in patients 
with cirrhosis and acute variceal bleeding.9
Platelets from patients with cirrhosis generate throm-
bin in a similar way to those from healthy controls, 
and patients with cirrhosis have pro-hemostatic fac-
tors (increased von-Willebrand factor and decreased 
ADAMTS-13, a protease that cleaves von-Willebrand 
factor).54 55 However, patients with cirrhosis often have 
thrombocytopenia as a result of splenic sequestra-
tion. The experimental finding that a platelet count of 
56×109/L leads to thrombin generation at the 10th centile 
of healthy control values54 provides the basis for giving 
platelet transfusions at around 50×109/L.4 7 However, no 
studies have assessed platelet thresholds or results with 
platelet transfusions, and some current guidelines state 
that no recommendation can be made regarding platelet 
transfusions.8 9
Pre-endoscopic medical therapy
The use of pre-endoscopic intravenous proton pump 
inhibitors (PPIs) has been assessed in several studies. A 
meta-analysis of six RCTs comprising 2223 patients found 
that the use of these drugs before endoscopy is associated 
with both reduced high risk stigmata of bleeding and the 
need for endoscopic therapy (odds ratio 0.68, 0.50 to 
0.93) but has no effect on patient outcomes, including 
rebleeding, need for surgery, or mortality (1.12, 0.72 to 
1.73).56 As a result, UK National Institute for Health and 
Care Excellence (NICE) guidelines do not support the 
routine use of these drugs before endoscopy.4 However, 
several other international guidelines suggest PPIs may 
have a role before endoscopy, particularly for patients in 
whom endoscopy may be delayed. 3 5 6 28 57
Prokinetic agents have been assessed for their ability 
to improve gastric emptying, thereby improving visu-
alization at endoscopy. Erythromycin, usually given as a 
250 mg infusion 30-120 minutes before endoscopy, has 
been most widely studied. The most recent meta-analysis 
of 598 patients in eight RCTs showed improved visuali-
zation, reduced need for second look endoscopy, and 
reduced length of hospital stay (mean difference −1.75 
days, 2.43 to −1.06) after erythromycin infusion before 
endoscopy.58
Tranexamic acid (TXA) inhibits the fibrinolytic activity 
of plasmin. A meta-analysis reported reduced mortality 
with TXA in patients with upper gastrointestinal bleed-
ing, but many studies were of poor quality and had been 
undertaken before the widespread use of PPIs and endo-
scopic therapy.59 Furthermore, other outcomes such as 
bleeding episodes and transfusions were not reduced. 
Therefore, it is difficult to draw firm conclusions from 
these data. A meta-analysis of two RCTs comprising 
40 138 patients with acute severe traumatic or postpar-
tum bleeding suggested even a short delay in the admin-
istration of TXA reduces benefit: immediate treatment 
improved survival (odds ratio 1.72, 1.42 to 2.10), but 
survival fell 10% with every 15 minutes delay, with no 
benefit beyond three hours.60 A large international study 
(HALT-IT) will finish recruitment shortly and the results 
should help clarify the role of TXA in upper gastrointes-
tinal bleeding.61
Pre-endoscopic medical therapy in patients with cirrhosis
Vasoactive drugs (terlipressin, somatostatin, or its ana-
logs octreotide and vapreotide), which cause splanch-
nic artery vasoconstriction, are used in patients with 
cirrhosis and variceal bleeding. When combined with 
endoscopic therapy, the different vasoactive drugs seem 
to have similar efficacy.62 Three double blind RCTs exam-
ined the use of vasoactive drugs (terlipressin, somatosta-
tin, and vapreotide) given before endoscopy in patients 
with cirrhosis and upper gastrointestinal bleeding.63-65 
Two studies reported less active bleeding at endoscopy 
in the active treatment group,64 65 and the third noted 
significantly more control of bleeding (clear gastric lav-
age and stable hemoglobin) at 12 hours with vasoactive 
drug therapy.63
Current guidelines recommend starting vasoactive 
drugs as soon as variceal hemorrhage is suspected.7-9 
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PPIs should not be given concurrently to patients who 
are receiving somatostatin (or analogs) because somato-
statin provides inhibition of gastric acid secretion compa-
rable to that provided by PPIs.66 67 Recommended doses 
are terlipressin 2 mg every four hours, somatostatin 250 
μg bolus followed by 250-500 μg/h, and octreotide and 
vapreotide 50 μg bolus followed by 50 μg/h.9 These drugs 
are generally given for up to five days.7-9
A meta-analysis of 12 RCTs compromising 1241 
patients showed that antibiotics reduce infections, 
rebleeding, and mortality (relative risk 0.79, 0.63 to 
0.98) in patients with cirrhosis and upper gastrointestinal 
bleeding.68 An RCT comparing intravenous ceftriaxone 
versus oral norfloxacin for seven days in 111 patients 
with advanced cirrhosis and gastrointestinal bleeding 
showed reduced proven infections with ceftriaxone (11% 
v 26%; P=0.03).69 However, the results may not be gener-
alizable to all patients with cirrhosis because only 9% of 
screened patients were enrolled. Current guidelines sug-
gest that antibiotics should be given from admission for 
up to seven days.7-9 Intravenous ceftriaxone is preferred 
in patients with advanced cirrhosis or those taking qui-
nolone prophylaxis and those in areas of high quinolone 
resistance, although the choice of antibiotic is dependent 
on local antimicrobial sensitivity patterns.7-9
Role of non-endoscopic diagnostic modalities before 
endoscopy
Because upper gastrointestinal bleeding can be diag-
nosed and treated with endoscopy, which is available in 
most hospitals, the role of other diagnostic modalities 
in patients presenting with an acute bleed is limited. In 
almost all cases, the initial diagnostic test will be upper 
endoscopy. Rarely, angiography or computed tomogra-
phy is used in patients who are not candidates for endos-
copy. However, these investigations are most commonly 
used if no source of bleeding is identified at endoscopy 
in patients with melena. A technetium-99m labelled red 
cell scan may also be used in this situation, but computed 
tomography angiography seems to be more accurate.70 71 
Early use of capsule endoscopy has been reported, with 
goals including stratifying risk and determining the timing 
of endoscopy,72 but more studies are needed to establish 
any potential role.
Timing of endoscopy
On the basis of improved outcomes in observational 
studies,3 5 28 guidelines recommend that, after appropri-
ate resuscitation, most patients who are admitted with 
upper gastrointestinal bleeding should undergo endos-
copy within 24 hours. Some guidelines suggest that 
patients with hemodynamic compromise and those with 
cirrhosis, who may have varices, undergo endoscopy 
within 12 hours after presentation,5 6 8 9 28 because some 
observational studies and subgroup analysis of an RCT 
provided limited evidence of improved outcome in high 
risk patients when endoscopy is performed within six to 
13 hours.73-75 Features that have been considered high 
risk include GBS ≥8-12, bloody gastric lavage or persis-
tent bloody emesis in hospital, hypotension, tachycardia, 
and comorbidities such as cirrhosis. However, evidence 
that can precisely identify high risk patients who should 
undergo early endoscopy is not available. In general, 
patients with persistent hemodynamic instability despite 
aggressive resuscitation will require urgent endoscopy.
Endoscopy should not be undertaken before the 
patient’s hemodynamic status is dealt with by initiating 
appropriate resuscitation and aiming to optimize comor-
bidities. This is illustrated by a recent observational study 
of 12 601 Danish patients with upper gastrointestinal 
bleeding secondary to peptic ulcers. This study suggested 
a survival benefit from delaying endoscopy for 12 hours in 
hemodynamically stable patients with American Society 
of Anesthesiologists score 3-5 (odds ratio 0.48, 0.34 to 
0.67), and for six hours in patients with hemodynamic 
instability (0.73, 0.54 to 0.98) (fig 3).76 Most deaths after 
upper gastrointestinal bleeding are caused by underlying 
comorbidities rather than exsanguination, so attention to 
other medical problems is key to patient management.77
Two small RCTs compared urgent (<2-6 h) with elective 
(>48 h) endoscopy for patients presenting with upper gas-
trointestinal bleeding who were hemodynamically stable 
and had no serious comorbidities.78 79 As expected in these 
low risk patients, no difference in clinical outcomes was 
identified. However, ~40-45% of patients had low risk 
endoscopic findings that would allow for early discharge. 
Thus, non-emergent endoscopy, undertaken as soon as 
possible within routine business hours, is recommended 
in low risk patients to allow safe early discharge in many 
of these patients.80
Endoscopic therapy
Non-variceal bleeding
Recommended modalities for ulcer bleeding include 
injection of epinephrine (eg, 1:10 000 dilution), injection 
$6$$6$ )LWWHGYDOXHV   7LPLQJK
0RUWDOLW\ 
 3 
Fig 3 |  Association between timing of endoscopy and mortality in hospital patients with 
hemodynamic instability after correction for confounding variables.76 Abbreviation: 
ASA=American Society of Anesthesiologists score.
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of sclerosants such as absolute ethanol, thermal contact 
devices such as bipolar electrocoagulation probes or 
heater probes, and through-the-scope clips.5 28 RCT data 
supporting efficacy in ulcer bleeding are more limited 
for non-contact thermal devices such as argon plasma 
coagulation.28 Vascular ectasias may also be treated 
with thermal methods, commonly argon plasma coagu-
lation; radiofrequency ablation is another thermal con-
tact modality sometimes used for gastric antral vascular 
ectasia.81
Endoscopic injection of epinephrine should not be 
used as a single modality treatment. Meta-analyses have 
reported lower rates of further bleeding with an alterna-
tive modality compared with epinephrine alone (relative 
risk 0.58, 0.36 to 0.93) and with epinephrine combined 
with a second modality versus epinephrine alone (relative 
risk 0.34, 0.23 to 0.50).82 83 Epinephrine can be used for 
temporary control of bleeding to aid visualization of the 
lesion before definitive treatment with another modal-
ity (such as a thermal or mechanical) or to decrease the 
risk of inducing bleeding with the application of a second 
modality.
Most data on non-variceal upper gastrointestinal bleed-
ing are from patients with peptic ulcer bleeding. The For-
rest classification of endoscopic stigmata is commonly 
used by endoscopists to identify higher risk lesions that 
require the application of endoscopic therapy.84 Endo-
scopic therapy significantly decreases further bleeding 
and the need for urgent intervention in patients with 
ulcers with spurting or oozing blood (Forrest 1a or 1b) or 
with non-bleeding visible vessels (Forrest 2a; fig 4A).28 
Patients with adherent clots (Forrest 2b) were not shown 
to benefit from endoscopic therapy in a meta-analysis of 
RCTs, but results of individual trials were very heteroge-
neous.80 This has led to guideline recommendations that 
either endoscopic plus medical therapy or medical man-
agement alone may be used for patients with adherent 
clots.5 28 Around 25-50% of patients admitted to hospital 
with bleeding ulcers have Forrest 1a, 1b, 2a, or 2b stig-
mata.76 85 Endoscopic treatment is not needed for ulcers 
with flat pigmented spots or a clean base (Forrest 2c or 
3).5 28
Variceal bleeding
Variceal bleeding accounted for 11% of patients admit-
ted to hospital with acute upper gastrointestinal bleed-
ing in a nationwide UK audit.15 However, the proportion 
of patients with variceal bleeding varies widely and is 
related to the proportion of people with liver disease in 
the population served. Patients with variceal bleeding 
have a higher mortality than those with non-variceal 
bleeding, and this is largely related to the severity of 
underlying liver disease.14 86
The optimal endoscopic therapy for esophageal variceal 
bleeding is variceal band ligation, which is associated 
with less rebleeding and fewer side effects than sclero-
therapy.4 7 9 87 If gastric varices are found, ligation can be 
used for gastroesophageal varices type-1, where esopha-
geal varices extend several centimeters distally along 
the gastric lesser curve. Injection of tissue adhesive (eg, 
N-butyl-cyanoacrylate) is the recommended endoscopic 
approach for all other types of gastric varices, although 
thrombin injection can be considered.7 9 88-90  Thrombin 
injection has been described for gastric variceal bleeding 
in cohort studies, but to date no RCTs have compared it 
with other treatments.91-93
Post-endoscopic management
PPI therapy
A meta-analysis of RCTs comparing PPIs to placebo or no 
therapy in high risk patients undergoing successful endo-
scopic therapy showed that high dose PPIs, usually given 
as an intravenous bolus of 80 mg followed by continu-
ous infusion at 8 mg/h for 72 hours, reduced rebleeding 
(relative risk 0.40, 0.28 to 0.59) and mortality (0.41, 0.20 
to 0.84). Intermittent intravenous or oral PPIs reduced 
rebleeding (0.53, 0.35 to 0.78) but not mortality.82 A 
Fig 4 |  (A) Endoscopic view of a large posterior duodenal ulcer with intermittent bleeding from 
a visible vessel. The patient, a middle aged man taking anticoagulant drugs, was admitted 
with hematemesis, hemodynamic instability, and a hemoglobin concentration of 55 g/L. 
After resuscitation, transfusion to hemoglobin 70-80 g/L, and correction of coagulopathy, 
endoscopy was undertaken. (B) Through-the-scope clips were applied after dilute epinephrine 
was injected into the four quadrants of the ulcer base. The fibrotic base made application of the 
clips problematic. (C) There was ongoing intermittent oozing of blood. Given the high risk ulcer, 
hemostatic powder spray was then applied to good effect. High dose intravenous proton pump 
inhibitors (PPIs) were given and the patient was managed in the hospital high dependency unit. 
Because of the clinical situation and the difficulty in providing endoscopic therapy to this large 
fibrotic ulcer, the plan for urgent referral for radiological embolization—should early rebleeding 
occur—was clearly documented by the endoscopist as a “rebleeding plan.” (D) Fifteen hours 
later the patient rebled and became hemodynamically unstable. He was again resuscitated 
appropriately, after which an interventional radiologist performed coil embolization of the 
gastroduodenal artery. The patient had no further bleeding and was restarted on anticoagulants 
on day 3. When he was discharged from hospital a week later he was still taking oral PPIs twice 
daily, but when the 14 day course was finished, the dose was reduced to once daily.
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meta-analysis of 13 studies found that a bolus followed 
by intermittent doses of intravenous or oral PPIs was non-
inferior to continuous infusion (further bleeding risk ratio 
0.72; one sided 95% confidence interval upper boundary 
0.97), although most individual studies were relatively 
small and not designed to answer this question.94 No 
conclusions could be made regarding oral versus intra-
venous dosing,94 although oral administration provides 
an antisecretory effect comparable to equivalent doses 
of intravenous PPIs.95 Guidelines have recommended an 
intravenous bolus followed by continuous infusion PPI 
therapy,3 5 6 28 although recent guidelines also suggest con-
sidering intermittent high doses of oral or intravenous PPI 
(eg, 80-160 mg daily in divided doses after an initial 80 
mg bolus), rather than continuous infusion.5 6
Patients with peptic ulcer bleeding generally receive 
four to eight weeks of once daily oral PPIs. Those with 
low risk endoscopic lesions (clean base, flat spot) should 
receive PPIs once a day from the time of diagnosis. Those 
with high risk endoscopic lesions and clinical features 
should receive high dose PPIs on days one to three as 
above, followed by twice daily oral PPI on days four to 
14. This regimen is based on an RCT of 187 patients that 
showed significantly less rebleeding with twice daily ver-
sus once daily PPIs (relative risk 0.41, 0.18 to 0.93) during 
this period.96
The benefits of PPIs outweigh potential risks when 
used after bleeding from a peptic ulcer. Multiple phar-
macodynamics studies report that omeprazole reduces 
the antiplatelet effect of clopidogrel, but a double blind 
placebo controlled trial in 3761 clopidogrel users found 
no evidence that omeprazole increased cardiovascular 
events (hazard ratio 0.99, 0.68 to 1.44).97 The US Food 
and Drug Administration recommends avoiding the use 
of omeprazole or esomeprazole in patients who are taking 
clopidogrel.98
Patients with cirrhosis and variceal bleeding
As noted above, in patients with cirrhosis and upper gas-
trointestinal bleeding, antibiotics should be continued 
for up to seven days,7-9 regardless of whether varices are 
identified as the source of the bleeding. Patients who have 
documented variceal bleeding at endoscopy should also 
have their vasoactive drugs continued for up to five days.7-9 
Combined treatment with endoscopic ligation and vasoac-
tive drugs is superior to ligation alone or vasoactive drugs 
alone in reducing further bleeding in hospital or during 
the first seven days after treatment.99 100
Transjugular intrahepatic portosystemic shunt (TIPS) 
may also be used after initial endoscopic therapy in the 
first three days after presentation for the treatment of acute 
esophageal variceal bleeding in patients with Child-Pugh 
class C cirrhosis (score 10-13)8 9 A multicenter RCT com-
pared early (within 72 h) TIPS placement versus standard 
treatment with variceal ligation plus drug therapy in 63 
patients with Child-Pugh C cirrhosis or Child-Pugh B cir-
rhosis with active bleeding. It reported that more patients 
were free from further bleeding at one year with early 
TIPS (97% v 50%; P<0.001).101 One year survival was 
also higher with early TIPS (86% v 61%; P<0.001) and 
encephalopathy was not increased. Subsequent reports 
suggest that the benefit is primarily in those with Child-
Pugh C disease.102 However the evidence for early TIPS 
remains relatively limited and the practicalities may be 
challenging for many units.
Reintroduction of antithrombotic drugs
Several studies suggest a survival benefit from continuing 
or reintroducing antithrombotic drugs after upper gastroin-
testinal bleeding.103 104 This is perhaps unsurprising given 
that mortality after presentation with a bleed is more often 
caused by underlying comorbidities, particularly cardio-
vascular disease, rather than the bleed itself.77 However, 
balancing the risks and benefits of reintroducing these 
drugs after a patient presents with upper gastrointestinal 
bleeding can be challenging. If an antithrombotic drug is 
reintroduced, a PPI is usually also administered.
Aspirin is the most widely studied antithrombotic drug 
in patients with upper gastrointestinal bleeding. Strati-
fication of patients must be based on whether aspirin is 
given for secondary or primary cardiovascular preven-
tion. This is because the benefit in secondary prevention 
is far greater than that for primary prevention, with a 
number needed to treat to prevent myocardial infarction, 
stroke, or vascular death of 67 versus 1745.80
A randomized study of 156 patients with peptic ulcer 
bleeding who had been taking aspirin for secondary 
prevention reported reduced mortality at eight weeks in 
those who continued aspirin compared with those who 
discontinued the drug (1.3% v 12.9%; difference 11.6%, 
3.7% to 19.5%).103 Therefore, current guidelines suggest 
continuing aspirin (or reintroducing the drug within three 
days for higher risk endoscopic lesions) once hemosta-
sis is achieved.4-6 105 106 It has been suggested that when 
aspirin has been prescribed for primary prophylaxis, it 
should be stopped in most patients because the bleed-
ing risk probably outweighs the cardiovascular benefit.28 
If primary prevention is still clinically required after the 
bleed, it can be reintroduced after the ulcer has healed, 
or earlier depending on the clinical situation.5
No randomized studies are available to guide clinicians 
on the reintroduction of thienopyridines (eg, clopidogrel) 
or anticoagulants. Recent guidelines suggest that for 
patients receiving dual antiplatelet therapy, at least one 
drug, usually aspirin, should be reintroduced early as 
above, with the second drug withheld for up to five days 
after hemostasis, or the timing discussed with a cardio-
vascular specialist.5 6 105
Similar to the situation with antiplatelet agents, obser-
vational studies in patients who develop upper gastro-
intestinal bleeding while taking warfarin indicate that 
those who restart warfarin have markedly lower rates of 
death and thromboembolic events, without a higher rate 
of recurrent bleeding, when compared with those whose 
warfarin is not restarted.104 107 Recent guidelines suggest 
restarting warfarin from “as soon as hemostasis is estab-
lished”6 to seven to 15 days after the bleeding event.5 The 
indication for anticoagulation should be assessed at the 
time of the bleed, with early reintroduction (zero to seven 
days) recommended in patients with a higher thrombo-
embolic risk.5 6 However, robust data on the optimal tim-
ing of reintroduction are not available.
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Data on the timing of the reintroduction of DOACs 
after bleeding has been controlled are limited, and this 
clearly depends on the balance of risk between rebleeding 
and thromboembolic events. Use of the CHA2DS2-VASC 
(Congestive heart failure, Hypertension, Age-2, Diabetes, 
Stroke/TIA-2, Vascular disease) and HAS-BLED (Hyper-
tension, Abnormal renal and liver function, Stroke, prior 
Bleeding, Labile INRs, Elderly (>65 years), Drugs and 
alcohol) scores may help in this situation.108-110 The recent 
Asia-Pacific guidelines suggest reintroducing DOACs in 
patients with a high thromboembolic risk as soon as 
hemostasis is achieved, although others have suggested 
that patients should have their anticoagulant restarted at 
day 7, with possible bridging therapy with low molecu-
lar weight heparin from days 2 to 7 in those with a low 
bleeding risk.6 In general, patients with an increased 
thromboembolic risk should have early reintroduction 
of antithrombotic drugs, because the risks and severity 
of thromboembolic events generally outweigh those of 
bleeding events.
Management of persistent or recurrent bleeding, including 
role of interventional radiology and surgery
Non-variceal bleeding
The results of an RCT comparing repeat endoscopic ther-
apy with surgery in 92 patients with recurrent peptic 
ulcer bleeding indicate that endoscopic therapy should 
be repeated when bleeding recurs after initial endoscopic 
control.111 This study reported similar mortality, although 
more patients had complications with surgery (36.4% v 
14.6%; P=0.03). For patients with persistent or refrac-
tory bleeding from non-variceal sources despite optimal 
standard endoscopic and medical therapy, the addition 
of hemostatic powder spray for temporary control (12-24 
h) or over-the-scope clips (OTSC) as a rescue modality is 
suggested, in parallel with ongoing resuscitation.5 6 112 113
For peptic ulcer bleeding not controlled by endoscopic 
therapy, two recent meta-analyses of observational stud-
ies that compared surgery with radiological interven-
tion reported lower rebleeding with surgery, but similar 
mortality and need for further interventions, although 
patients receiving radiological intervention were older 
and in worse general health.114 115 Because many patients 
with recurrent bleeding are elderly with comorbidities, 
interventional radiology is generally preferred if locally 
available. Therefore, if bleeding continues despite opti-
mal endoscopic therapy, transarterial embolization is 
recommended, although surgery should be considered if 
radiological therapy is likely to be delayed.4 5
Prophylactic transarterial embolization of high risk 
ulcers after endoscopic therapy is not recommended: it 
did not significantly reduce rebleeding when compared 
with standard treatment (10.2% v 11.4%) in an RCT of 
241 patients.116
Variceal bleeding
Patients with rebleeding after initial endoscopic and 
medical therapy for varices may have repeat endoscopic 
therapy performed.8 TIPS is recommended for those with 
persistent or severe recurrent bleeding.7-9 For patients 
with severe bleeding refractory to endoscopic therapy, 
balloon tamponade has been recommended as a tempo-
rary bridge to definitive therapy.7 8 However, balloon tam-
ponade is associated with serious complications (such as 
esophageal rupture and aspiration pneumonia) in about 
12% of patients and its use was lethal in 6% of patients 
in a case series.117 Recently, removable self expanding 
covered metal esophageal stents designed for the treat-
ment of severe esophageal variceal bleeding have become 
available (although they are not approved in the US). An 
RCT of 28 patients compared these stents with balloon 
tamponade in patients with esophageal variceal bleed-
ing refractory to medical and endoscopic therapy and 
showed that the stents led to improved bleeding control 
(85% v 47%; Fisher’s exact test P=0.055), with similar 
mortality.118
Emerging treatments
Hemostatic powder spray
Hemostatic powder spray provides high rates of initial 
hemostasis for active non-variceal upper gastrointestinal 
bleeding, but with relatively high rebleeding rates, sug-
gesting a temporary effect.119-123 A systematic review of 
195 cases reported initial hemostasis in 92% and a seven 
day rebleeding rate of 21%.112 Currently, hemostatic 
powder is often used as a temporary rescue treatment 
for bleeding that cannot be controlled using established 
methods, and it may have a role for the initial control 
of diffuse bleeding from tumors.6 112 More limited data 
are available on hemostatic powder spray for variceal 
bleeding, often as a temporizing method until definitive 
therapy is applied.124
Over-the-scope clips
Treatment with OTSC is another relatively new technique. 
These clips are much larger than standard through-the-
scope clips so may be successful when applied to larger 
fibrotic lesions or larger feeding vessels. A multicenter 
RCT of 66 patients with recurrent ulcer bleeding after ini-
tial hemostasis showed that significantly fewer patients 
treated with OTSC had further bleeding compared with 
those on standard therapy (15% v 58%; difference 42%, 
22% to 63%).125 Further data are awaited, but at present 
OTSC may be considered as a rescue therapy when stand-
ard therapies do not achieve permanent hemostasis.
Doppler probes
Endoscopic Doppler probes have also been studied as a 
guide to endoscopic therapy. A recent dual center RCT 
of 148 patients with severe non-variceal upper gastro-
intestinal bleeding that compared endoscopic therapy 
guided by Doppler probe positive signals with standard 
endoscopic therapy guided by endoscopic stigmata found 
reduced 30 day rebleeding with Doppler guided therapy 
(11.1% v 26.3%; P=0.02).126 Further data on the clinical 
utility and practicalities of this approach are needed, and 
currently the use of these probes is not recommended by 
guidelines.5 6
Guidelines
As already noted, international, UK (NICE), American, 
European, and Asia-Pacific guidelines on upper gastro-
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intestinal bleeding (non-variceal and variceal) have been 
published over the past eight years. We have therefore 
referenced them as appropriate throughout. The most 
recent ones—the European (2015) and Asia-Pacific 
(2018) guidelines on non-variceal bleeding, and the 
UK, international, and US guidelines on variceal bleed-
ing—differ slightly from earlier ones, largely because they 
assessed more recently published studies (table). These 
guidelines have generally been written by experts in this 
field, although methodology has varied.
Conclusions
Upper gastrointestinal bleeding remains a common cause 
of presentation to hospitals worldwide, and many recent 
studies have assessed the management of patients with 
this condition. The evidence of improved outcomes from 
a relatively restrictive approach to blood transfusion and 
the ability to identify patients who are at very low risk and 
suitable for outpatient management have recently altered 
clinical practice, and these alterations to management are 
now recommended by international guidelines. RCTs and 
meta-analyses confirm a benefit from pre-endoscopy anti-
biotics and vasoactive drugs in patients with cirrhosis, 
and post-endoscopy high dose PPIs for high risk peptic 
ulcer bleeding.
Endoscopic therapy has advanced dramatically over the 
past decades, with recent additions to the endoscopist’s 
“toolkit,” including hemostatic powder spray, over-the-
scope clips, and Doppler probes. These join the estab-
lished and widely studied injection therapies, thermal 
probes, and clips used for non-variceal bleeding, and 
endoscopic band ligation and tissue adhesive injection 
for variceal bleeding. However, the newer modalities 
require further study to clarify their exact role in endo-
scopic management. Technical improvements and more 
widely available services for interventional radiology have 
led to it being the most commonly used rescue therapy 
for persistent or recurrent upper gastrointestinal bleeding 
that is refractory to endoscopic treatment. Surgery is now 
typically reserved for situations in which interventional 
radiology is unavailable, delayed, or unsuccessful.
The more widespread use of antiplatelet and anti-
coagulants drugs has led to uncertainty in managing 
patients taking these medications who develop upper 
gastrointestinal bleeding. However, recent data suggest 
that relatively early reintroduction of these drugs once 
hemostasis has been achieved is the best approach in 
those with appropriate cardiovascular indications. New 
approaches under investigation for managing upper 
gastrointestinal bleeding include the early use of TXA 
and novel endoscopic techniques to reduce rebleeding. 
These and other developments will hopefully continue 
to improve management and outcomes for patients with 
upper gastrointestinal bleeding.
Recommendations from major published guidelines on non-variceal UGIB
Guideline Risk scoring Prokinetics Pre-endoscopy PPIs Timing of endoscopy Post-endoscopy PPIs
International, 
20103
Prognostic scales recommended to 
identify high and low risk groups
Promotility agents 
should not be used 
routinely
May be considered but should not 
delay endoscopy
Within 24 h for most patients IV PPI bolus then infusion if 
high risk stigmata and have had 
successful endoscopic therapy
US, ACG (ulcer 
bleeding only) 
201228
Carry out risk assessment to stratify 
into higher and lower risk groups. 
Consider discharge from ED if GBS=0
Consider IV 
erythromycin
IV PPIs may be considered Within 24 h after resuscitation. 
Consider within 12 h if high risk 
features (eg, hemodynamic instability, 
bloody emesis in hospital)
After successful endoscopic 
hemostasis, give IV PPI bolus 
then infusion to those with active 
bleeding, NBVV, or adherent clot
US, ASGE 
201257
No specific recommendation but 
notes that GBS=0 identifies a very low 
risk group
Suggest IV prokinetic 
if high probability of 
fresh blood or clot in 
stomach
IV PPIs recommended Depends on clinical factors but 
recommends within 24 h in the 
presence of cancer, cirrhosis, 
hematemesis, hypovolemia, or Hb 
<80 g/L
IV PPI bolus then infusion after 
endoscopic therapy for ulcers with 
high risk stigmata
UK, NICE 20124 Use GBS before endoscopy and 
full Rockall score after endoscopy. 
Consider early discharge if GBS=0
Not assessed Do not give PPIs before endoscopy Within 24 h, but immediately after 
resuscitation if unstable and severe 
UGIB
Offer PPIs if stigmata of recent 
bleeding seen at endoscopy
Europe, ESGE 
20155
Patients with GBS 0-1 do not require 
early endoscopy or admission
Recommend IV 
erythromycin if 
clinically severe or 
ongoing active UGIB
IV bolus then infusion but should 
not delay endoscopy
Within 24 h of resuscitation, but 
consider within 12 h if high risk 
features (eg, hemodynamic instability 
despite resuscitation, inpatient bloody 
emesis, contraindication to stopping 
anticoagulants)
IV PPI bolus then 72 h infusion for 
patients who receive endoscopic 
hemostasis and those with 
adherent clots. Consider giving 
PPIs as intermittent IV bolus or 
high dose oral
Asia-Pacific, 
20186
Use GBS; adopting a cut off at GBS 
≤1 allows most hospitals to reduce 
unnecessary admissions
Not assessed IV PPIs recommended if suspected 
UGIB awaiting endoscopy 
(especially if endoscopy is not 
available within 24 h)
Within 24 h, but urgent (within 12 
h) if hemodynamic instability, after 
resuscitation and stabilization
After endoscopic hemostasis is 
achieved high dose oral PPIs can 
be used for 72 h as an alternative 
to high dose IV PPIs
Abbreviations: ACG=American College of Gastroenterology; ASGE=American Society for Gastrointestinal Endoscopy; ED=emergency department; ESGE= European Society of Gastrointestinal Endoscopy; 
GBS=Glasgow Blatchford score; Hb=hemoglobin; NBVV=non-bleeding visible vessel; NICE=National Institute for Health and Care Excellence; PPIs=proton pump inhibitors; IV=intravenous; UGIB=upper 
gastrointestinal bleeding.
QUESTIONS FOR FUTURE RESEARCH
• What is the optimal approach to fluid resuscitation in 
patients with acute upper gastrointestinal bleeding?
• Can risk assessment tools be developed to allow accurate 
early identification of high risk patients with upper 
gastrointestinal bleeding, such as those who require 
endoscopic therapy or those with high mortality?
• What is the optimal timing of endoscopy after upper 
gastrointestinal bleeding?
• What is the exact role of hemostatic powder spray, 
over-the-scope clips, and Doppler ultrasound probes in 
the endoscopic management of upper gastrointestinal 
bleeding?
• When is the best time to reintroduce antithrombotic drugs 
after upper gastrointestinal bleeding?
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